免责声明: 本站汇总 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公开数据,仅供一般参考,不构成医疗建议、诊断、治疗建议或投资建议。

临床试验

BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction

NCT:NCT02880618 · RECRUITING

NCT编号NCT02880618
状态RECRUITING
开始日期2016-12-13
SponsorCVRx, Inc. (INDUSTRY)
First posted
Last updated

简要摘要

The purpose of this registry (NCT02880618) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for heart failure with reduced ejection fraction (HFrEF).

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态,请参阅官方记录。

↑